Diklovit 50mg 10 Pieces suppositories


Diklovit 50mg 10 Pieces suppositories



Active substance:
1 suppository contains diclofenac sodium – 50 mg.
hard fat (Witepsol grade H 15, W 35, Supposir mark NA 15, NAS 50) – to obtain a suppository weighing 1.26 g
Suppositories are white or almost white, torpedo-shaped. It allowed the appearance of white deposits on the surface of the suppository.
Product form:
50 mg rectal suppositories.
5 suppositories in blisters. Two blisters with instruction for medical use of the formulation was put in a pile of cardboard.
Hypersensitivity (including to other. NSAIDs), erosive and ulcerative lesions of the gastrointestinal tract (exacerbation), bleeding from the gastrointestinal tract, “Aspirin” asthma, breach of hemopoiesis, hemostatic disorders (including hemophilia), pregnancy, children’s age (15 years), lactation, rectal bleeding, hemorrhoids, trauma, or inflammation of the rectum.
50 mg
Diseases of the musculoskeletal system (rheumatoid arthritis, psoriatic, juvenile chronic arthritis, ankylosing spondylitis, gouty arthritis, rheumatic soft tissue, osteoarthritis of peripheral joints and spine, including radicular syndrome, tenosynovitis, bursitis).
Pain syndrome weak or moderate severity: neuralgia, myalgia, sciatica, post-traumatic pain, accompanied by inflammation, postoperative pain, headache, migraine, tuberculosis, adnexitis, toothache.
In the combined therapy of infectious and inflammatory diseases of the ear, nose and throat with severe pain (pharyngitis, tonsillitis, otitis media).
Interaction with other drugs
Increasing the concentration of digoxin in plasma of methotrexate drugs lithium and cyclosporine.
Reduces the effect of diuretics, potassium-sparing diuretics in the background increases the risk of hyperkalemia; against the background of anticoagulants, thrombolytic agents (alteplase, streptokinase, urokinase) – The risk of bleeding (usually from the gastrointestinal tract).
Reduces the effect of antihypertensive and hypnotic drugs.
It increases the likelihood of side effects of other nonsteroidal anti-inflammatory drugs and glucocorticosteroid means (bleeding in the gastrointestinal tract), the toxicity of methotrexate and cyclosporine nephrotoxicity.
Acetylsalicylic acid reduces the concentration of diclofenac in the blood.
Simultaneous use of paracetamol with increased risk of nephrotoxic effects of diclofenac.
Reduces the effect of hypoglycemic agents.
Cefamandole, cefoperazone, cefotetan, valproic acid and increase the incidence plicamycin hypoprothrombinemia.
Cyclosporine and preparations of gold increases the effect of diclofenac on the synthesis of prostaglandins in the kidneys, which increases the nephrotoxicity.
Simultaneous with the appointment ethanol, colchicine, corticotropin and drugs St. John’s wort increases the risk of bleeding in the gastrointestinal tract.
Diclofenac enhances the action of drugs that cause photosensitization.
Drugs that block tubular secretion, increase the concentration of diclofenac in plasma, thereby increasing its toxicity.
Symptoms: dizziness, headache, shortness of breath, dizziness, children – myoclonic seizures, nausea, vomiting, abdominal pain, bleeding, abnormal liver function and kidney.
Treatment: activated charcoal, symptomatic therapy. Forced diuresis, hemodialysis ineffective.
pharmachologic effect
Pharmacological group:
Nonsteroidal anti-inflammatory drug (NSAID).
Pharmacological properties:
Diclofenac possesses anti-inflammatory, analgesic and antipyretic action. Non-selectively inhibiting cyclooxygenase 1 and 2, it gives the arachidonic acid metabolism, reduces the amount of prostaglandins in inflammation. In rheumatic diseases inflammatory and analgesic effect of diclofenac contributes to a significant reduction in the severity of pain, morning stiffness, swelling of the joints, which improves the functional state of the joint. When trauma, postoperative diclofenac reduces pain and inflammatory edema. In primary algodismenoree reduces pain and bleeding.
The maximum plasma concentration is created over 30-40 minutes and stored in a linear dependence on the dose used. Changes in the pharmacokinetics of diclofenac on the background of multiple doses is not marked, not accumulates.
Relationship to plasma proteins – more than 99% (most associated with albumin). Penetrates into the synovial fluid. The maximum concentration in the synovial fluid is observed in 2-4 hours later than in plasma. The half-life of synovial fluid W h-b (active ingredient concentration in the synovial fluid after 4-6 h after administration is higher than in the plasma, and remains higher for a further 12 hours). The relationship of drug concentration in the liquid sinovilnoy clinical efficacy of the drug is not clear.
Metabolism: 50% of the active substance is metabolised during the “first pass” through the liver. Metabolism occurs as a result of single or multiple hydroxylation and conjugation with glucuronic acid. The metabolism of the drug is involved enzyme system P450 CYP2C9. The pharmacological activity of the metabolites is lower than diclofenac.
. The half-life of plasma – 2 hours 65% of the administered dose excreted by the kidneys as metabolites; less than 1% is excreted in unaltered form, the remainder of the dose excreted in bile as metabolites.
In patients with renal failure (less than 10 ml / min creatinine clearance) increases the excretion of metabolites in the bile, thus increasing their concentration in the blood is not observed.
In patients with chronic hepatitis or compensated cirrhosis pharmacokinetic parameters of diclofenac are not changed.
Diclofenac passes into breast milk.
Conditions of supply of pharmacies
On prescription.
side effects
Occurring side effects depend on the individual sensitivity, the values ​​of the applied dose and duration of treatment. The term “sometimes” is used if the side effects have been reported in 1-10% of patients, “seldom” – at 0.001-1% of patients.
Gastrointestinal tract:
Sometimes – abdominal pain, a feeling of bloating, diarrhea, nausea, constipation, flatulence, increased levels of “liver” enzymes, peptic ulcer with possible complications (bleeding, perforation), gastrointestinal bleeding;
Rarely – vomiting, jaundice, melena, blood in stool, esophageal lesion, aphthous stomatitis, dry mouth, mucosal, hepatitis (fulminant possible), necrosis of the liver, cirrhosis, hepatorenal syndrome, appetite change, pancreatitis, holetsistopankreatit, colitis.
Nervous system:
Sometimes – headache, dizziness;
Rarely – sleep disturbance, drowsiness, depression, irritability, aseptic meningitis (usually in patients with systemic lupus erythematosus and other connective tissue diseases), cramps, weakness, disorientation, nightmares, feeling of fear.
Senses: sometimes – ringing in the ears;
Rarely – blurred vision, diplopia, disturbance of taste, reversible or irreversible hearing loss, scotoma.
Sometimes – itching, skin rash;
Rarely – areata, urticaria, eczema, chronic dermatitis, erythema multiforme, including Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell’s syndrome), increased photosensitivity melkotochechnye hemorrhage.
Genito-urinary system: sometimes – fluid retention;
Rarely – nephrotic syndrome, proteinuria, oliguria, hematuria, interstitial nephritis, papillary necrosis, acute renal failure, azotemia.
Bodies of hematopoiesis and immune system:
Sometimes – anemia (including haemolytic and aplastic anemia), leukopenia, thrombocytopenia, eosinophilia, agranulocytosis, thrombocytopenic purpura, worsening of infectious processes (development of necrotising fasciitis).
Respiratory system:
Rarely – cough, bronchospasm, laryngeal edema, pneumonitis.
The cardiovascular system:
Rarely – increased blood pressure; congestive heart failure, beats, chest pain.
Allergic reactions:
Rare – anaphylactoid reaction, anaphylactic shock (usually develops rapidly), swelling of the lips and tongue, allergic vasculitis.
Local reactions at the rectal:
Rare – irritation of the mucous membrane of the rectum, mucous discharge mixed with blood, pain during bowel movements, rectal bleeding.
special instructions
Patients receiving the drug should refrain from activities requiring increased attention and rapid mental and motor reactions, the use of alcohol.
Storage conditions
At temperatures above 25 ° C.
Keep out of the reach of children.
Dosing and Administration
Suppositories are administered in rectum preferably after spontaneous bowel movement or enema. After introduction of the suppository is recommended to stay in bed for 20-30 minutes.
Adults and adolescents from 15 years: 1 suppository 2-3 times a day.
The simultaneous use of the drug with the oral forms Diklovit® diclofenac sodium. The total daily dose of diclofenac sodium should not exceed 150 mg.
When algodismenoree (when the first symptoms), the initial dose of 50-100 mg / day (1 suppository 1-2 times a day), if necessary, the dose is increased over several menstrual cycles and 150 mg (1 suppository 3 times a day).
Migraine – 100 mg (suppository 2) at the first sign of attack.
If necessary – re (100 mg, 2 suppository).
If necessary, further treatment in the next days the daily dose should not exceed 150 mg (3 suppository) per day.
The duration of treatment determined by the doctor depending on the severity of the disease.
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg


There are no reviews yet.

Add your review